Meta-regression analysis of paroxetine clinical trial data: Does reporting scale matter?

Journal of Clinical Psychopharmacology

Volumn 31, Issue 2, 2011, Pages 201-206

  Klemp, Marianne ^a   Tvete, Ingunn F ^a   Gåsemyr, Jørund ^a   Natvig, Bent ^a   Aursnes, Ivar ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

antipsychotics; meta regression analysis; paroxetine; regression to the mean

Indexed keywords

PAROXETINE; PLACEBO;

ARTICLE; BIPOLAR DEPRESSION; DEPRESSION; HAMILTON SCALE; HUMAN; META ANALYSIS; PATIENT SELECTION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS;

DEPRESSIVE DISORDER, MAJOR; HUMANS; PAROXETINE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79952445895     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318210bac1     Document Type: Article

References (22)

1. Barbui C, Furukawa T, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ. 2008;178:296-305. (Pubitemid 351212875)
2. Kirsch I, Deacon B, Huedo-Medina T, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45.
3. National Institute for Clinical Excellence. Management of Depression in Primary and Secondary Care. Clinical Practice Guideline No. 23. London, UK: National Institute for Clinical Excellence; 2004:1-16.
4. Gottlieb SS, Kop WJ, Thomas SA, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J. 2007;153:868-873. (Pubitemid 46602150)
5. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287:1840-1847. (Pubitemid 34303629)
6. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19:34-40.
7. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303:47-53.
8. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
9. Gibbons RD, Clark DC, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res. 1993;27:259-273. (Pubitemid 23344947)
10. Miller IW, Bishop S, Norman W, et al. The modified Hamilton rating scale for depression: reliability and validity. Psychiatr Res. 1985; 14:131-142. (Pubitemid 15138581)
11. GSK. Clinical Study Register. Available at: http://www.gsk- clinicalstudyregister.com/. Accessed February 8, 2010.
12. Lilly. Clinical Trial Results. Available at: http://www.lillytrials.com/ results/results.html/. Accessed February 8, 2010.
13. Detke M, Wiltse C, Mallinckrodt C, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004; 14:457-470. (Pubitemid 39626894)
14. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17:239-247.
15. Hedges LV. Distribution theory for Glass's estimator of effect size and related estimators. J Educ Stat. 1981;6:107-128.
16. Whitehead A. Meta-analysis of Controlled Clinical Trials. London, UK: John Wiley & Sons, Ltd; 2002.
17. Viechtbauer W. MiMa. An S-Plus/R function to fit meta-analytic mixed-, random-, and fixed-effects models. Available at: http://www.wvbauer.com/. Accessed February 8, 2010.
18. Cheung MW. A model for integrating fixed-, random-, and mixed-effects meta-analyses into structural equation modeling. Psychol Methods. 2008;13:182-202.
19. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18:2693-2708. (Pubitemid 29481404)
20. Casella G, Berger RL. Statistical Inference. Pacific Grove, CA: Duxbury Press; 2001.
21. Reif A, Fritzen S, Finger M, et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry. 2006;11:514-522.
22. Thompson S, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559-1573. (Pubitemid 34746063)